Altered Pharmacokinetics of Piperacillin in Febrile Neutropenic Patients with Hematological Malignancy

Fekade Bruck Sime; Michael S Roberts; Morgyn S Warner; Uwe Hahn; Thomas A Robertson; Sue Yeend; Andy Phay; Sheila Lehman; Jeffrey Lipman; Sandra L Peake; Jason A Roberts

doi:10.1128/AAC.02340-14

Retour

Altered Pharmacokinetics of Piperacillin in Febrile Neutropenic Patients with Hematological Malignancy

Article de revue

Avec comité de lecture

Altered Pharmacokinetics of Piperacillin in Febrile Neutropenic Patients with Hematological Malignancy

Fekade Bruck Sime, Michael S Roberts, Morgyn S Warner, Uwe Hahn, Thomas A Robertson, Sue Yeend, Andy Phay, Sheila Lehman, Jeffrey Lipman, Sandra L Peake, …

Antimicrobial agents and chemotherapy, Vol.58(6), pp.3533-3537

01/06/2014

DOI: https://doi.org/10.1128/AAC.02340-14

PMID: 24687508

Résumé

Anti-Bacterial Agents

Fever

Hematologic Neoplasms

Neutropenia

Pharmacology

Piperacillin

This study assessed the pharmacokinetics and dosing adequacy of piperacillin in febrile neutropenic patients after the first dose. Pharmacokinetic analysis was performed using noncompartmental methods. We observed an elevated volume of distribution (29.7 ± 8.0 liters [mean ± standard deviation]) and clearance (20.2 ± 7.5 liters/h) compared to data from other patient populations. Antibiotic exposure did not consistently result in therapeutic targets. We conclude that alternative dosing strategies guided by therapeutic drug monitoring may be required to optimize exposure.

Indicateurs

1 Consultations de la notice

See more details

Détails

Titre: Altered Pharmacokinetics of Piperacillin in Febrile Neutropenic Patients with Hematological Malignancy
Créateurs - sans rôle: Fekade Bruck Sime - Basil Hetzel Institute
Michael S Roberts - Therapeutics Research Centre, Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Adelaide, Australia
Morgyn S Warner - SA Pathology and the University of Adelaide, Adelaide, Australia
Uwe Hahn - Department of Haematology/Oncology, The Queen Elizabeth Hospital, Adelaide, Australia
Thomas A Robertson - Therapeutics Research Centre, Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Adelaide, Australia
Sue Yeend - Cancer Clinical Trials, The Queen Elizabeth Hospital, Adelaide, Australia
Andy Phay - Cancer Clinical Trials, The Queen Elizabeth Hospital, Adelaide, Australia
Sheila Lehman - Department of Haematology/Oncology, The Queen Elizabeth Hospital, Adelaide, Australia
Jeffrey Lipman - Burns, Trauma, and Critical Care Research Centre, University of Queensland, Herston, Brisbane, Queensland, Australia
Sandra L Peake - Department of Intensive Care Medicine, The Queen Elizabeth Hospital, Adelaide, Australia
Jason A Roberts - Burns, Trauma, and Critical Care Research Centre, University of Queensland, Herston, Brisbane, Queensland, Australia
Détails de publication: Antimicrobial agents and chemotherapy, Vol.58(6), pp.3533-3537
Éditeur: American Society for Microbiology
Nombre de pages: 5
Identifiants: 99153865809311
Unité académique: Initial MAnagement & prevent of acute orGan failures IN critically ill patiEnts - IMAGINE
Langue: English
Type de ressource: Journal article